MHLW Lifts Conditions On Banyu's Hyperlipidemia Drug Lipovas
This article was originally published in PharmAsia News
Executive Summary
The first section on drugs of the Pharmaceutical Affairs and Food Sanitation Council at the Ministry of Health, Labor and Welfare lifted conditions on Banyu Pharmaceutical's hyperlipidemia drug Lipovas (simvastatin). Imposed upon approval in 2001, the conditions required Banyu to study the relationship between increased dosage and the onset of rhabdomyolysis, but no cases of rhabdomyolysis have been reported and creatine kinase counts, directly related to the disease, are lower after market launch compared to those reported in clinic trials. (Click here for more - Japanese language)
You may also be interested in...
Banyu To Conduct Major Marketing Restructuring; Considers Job Cuts
TOKYO - Merck's Japanese subsidiary Banyu Pharmaceutical said Sept. 17 that it will streamline its marketing structure and consolidate its branches and business offices into 20 locations and assign sales staff to sell drugs by illness, instead of the industry tradition of regional sales
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.